Novartis To Buy Neuroscience Therapy Biz For Up To $770M
Swiss pharmaceutical giant Novartis AG said Thursday it will acquire neuroscience company Cadent Therapeutics for up to $770 million, including a $210 million up-front payment....To view the full article, register now.
Already a subscriber? Click here to view full article